Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
4.660
-0.080 (-1.69%)
At close: Mar 20, 2026, 4:00 PM EDT
4.660
0.00 (0.00%)
After-hours: Mar 20, 2026, 4:03 PM EDT
Niagen Bioscience Revenue
In the year 2025, Niagen Bioscience had annual revenue of $129.42M with 29.95% growth. Niagen Bioscience had revenue of $33.84M in the quarter ending December 31, 2025, with 16.19% growth.
Revenue (ttm)
$129.42M
Revenue Growth
+29.95%
P/S Ratio
2.86
Revenue / Employee
$1,106,179
Employees
117
Market Cap
373.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 129.42M | 29.83M | 29.95% |
| Dec 31, 2024 | 99.60M | 16.03M | 19.18% |
| Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
| Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
| Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
| Dec 31, 2020 | 59.26M | 12.97M | 28.01% |
| Dec 31, 2019 | 46.29M | 14.73M | 46.69% |
| Dec 31, 2018 | 31.56M | 10.36M | 48.85% |
| Dec 30, 2017 | 21.20M | -463.65K | -2.14% |
| Dec 31, 2016 | 21.66M | 3.78M | 21.13% |
| Jan 2, 2016 | 17.88M | 2.57M | 16.79% |
| Jan 3, 2015 | 15.31M | 5.15M | 50.71% |
| Dec 28, 2013 | 10.16M | -1.45M | -12.48% |
| Dec 29, 2012 | 11.61M | 3.50M | 43.12% |
| Dec 31, 2011 | 8.11M | 546.24K | 7.22% |
| Jan 1, 2011 | 7.57M | 1.79M | 30.95% |
| Jan 2, 2010 | 5.78M | 1.27M | 28.22% |
| Jan 3, 2009 | 4.51M | -247.77K | -5.21% |
| Dec 29, 2007 | 4.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Enanta Pharmaceuticals | 66.98M |
| Autolus Therapeutics | 51.13M |
| X4 Pharmaceuticals | 35.11M |
| Lineage Cell Therapeutics | 14.56M |
| PureTech Health | 6.39M |
| YD Bio | 510.36K |
NAGE News
- 1 day ago - Niagen Bioscience Increases Share Repurchase Program to $20 Million - Business Wire
- 2 days ago - Niagen Bioscience to Present at the 38th Annual ROTH Conference - Business Wire
- 3 days ago - Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies - Business Wire
- 10 days ago - Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen® - Business Wire
- 15 days ago - Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 - Business Wire
- 22 days ago - Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction - Business Wire
- 23 days ago - Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen® - Business Wire